PCI Pharma Services, a global contract development and manufacturing organisation (CDMO), has released its first Environmental, Social & Governance (ESG) Report, which includes a detailed overview of PCI’s sustainability journey.
The report showcases the movements taken from the program’s formal inception in 2021 through its 2023 fiscal year, and lays out goals for continued progress along multiple fronts.
The report discloses PCI’s performance, targets and strategy to achieve nine identified impact categories, from sustainability-focused practices concerning carbon footprint, responsible waste management and eco-conscious procurement to people-first issues such as health and safety, community impact and DEI.
PCI’s ESG initiatives are intended to purposefully impact the many local and global communities it interacts with, cares for and serves.
True to this mindset, PCI Pharma’s ESG program is inherently inclusive and bottom-up. The report includes PCI’s approach to a Double Materiality Assessment, which gathers input from hundreds of employees as well as external stakeholders including customers, supplier partners, investors and community organisations.
The purpose of this assessment is to identify those ESG elements important to and emphasised by all stakeholders and — from there — to focus on meaningful and measurable progress against those critical factors.
Encouragingly, the Double Materiality Assessment indicated that the majority of PCI’s ESG impact categories are in alignment with its stakeholders’ priorities. Even so, the assessment results were insightful and were taken into account to ensure long-term alignment between stakeholder priorities and PCI’s ESG strategy.
Other highlights from PCI’s ESG report include:
- Emission reduction targets
- Water conservation
- Waste management
- Community Impact
- Organisation-wide diversity and inclusion measures
